NDA 020497 · Kyowa Kirin
Fareston
Toremifene Citrate · Oral
NovelOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
May 29, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
38
17 Phase 3, 5 recruiting
FAERS reports
431
374 serious, 57 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: QT PROLONGATION FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [see Warnings and Precautions (5.1) ] . WARNING: QT PROLONGATION FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner [see Clinical Pharmacology (12.2) ] . Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or...
What it is approved for
From the label in effect Nov 13, 2024.
FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. ( 1 )
Mechanism: Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly antiestrogenic in rats and humans and estrogenic in mice. In rats, toremifene causes regression of established dimethylbenzanthracene (DMBA)-induced mammary tumors. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 1997 Original approval · Type 1 - New Molecular Entity
1 products under this application
- FARESTON · TOREMIFENE CITRATE EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Toremifene" as an intervention, any sponsor and status, largest first.
- Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer PatientsPivotal-lookingStatus unknown
Fengxi SuAcademic, hospital or other
NCT02132000 · 3,036 participants (planned) · Start Apr 2014 · Primary completion May 2020
Drug: toremifene or tamoxifen · For: Breast Cancer Patients in Premenopausal; Estrogen and/or Progesterone Receptor Positive
Sites: Guangzhou, China
- De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07153757 · 2,934 participants (planned) · Start Sep 1, 2025 · Primary completion Sep 1, 2033
Drug: Endocrine Therapy of Physician's Choice · For: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Sites: Shanghai, China
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyPivotal-lookingRecruiting
Fujian Cancer HospitalGovernment (non-federal)
NCT07581834 · 2,000 participants (planned) · Start Jan 21, 2026 · Primary completion Dec 31, 2031
Drug: Dalpiciclib 125mg; Dalpiciclib 100mg and 1 more · For: Breast Diseases; Breast Neoplasms; Dalpiciclib and 3 more
Sites: Fuzhou, China; Chengdu, China
- Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)Pivotal-lookingCompleted
GTxIndustry
NCT00106691 · 1,589 participants · Start Jan 2005 · Primary completion Feb 2010
Drug: Toremifene 20 mg; Placebo · For: Preneoplastic Conditions; Prostatic Intraepithelial Neoplasia
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 138 sites in all
- Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation TherapyPivotal-lookingCompleted
GTxIndustry
NCT00129142 · 1,200 participants · Start Oct 2003 · Primary completion Nov 2007
Drug: Toremifene Citrate · For: Prostate Cancer; Osteoporosis; Fractures
Sites: Homewood, Alabama; Mobile, Alabama; Little Rock, Arkansas · 155 sites in all
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05861271 · 1,008 participants (planned) · Start Jun 1, 2023 · Primary completion Jul 1, 2026
Drug: Capecitabine,Pyrotinib · For: Breast Cancer Stage I
Sites: Shanghai, China
- Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerPivotal-lookingCompleted
Intarcia TherapeuticsIndustry
NCT00044291 · 865 participants · Start Jun 2002 · Primary completion Jan 2006
Drug: atamestane; toremifene and 2 more · For: Breast Neoplasms; Neoplasms, Hormone-dependent
Sites: Lake Havasu City, Arizona; Tucson, Arizona; Greenbrae, California · 63 sites in all
- Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast CancerPivotal-lookingStatus unknown
Chinese Anti-Cancer AssociationAcademic, hospital or other
NCT03351062 · 844 participants (planned) · Start Nov 2017 · Primary completion Dec 2025
Drug: Tamoxifen; Toremifene · For: Breast Cancer Female
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 21 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hepatic function abnormal22
- interstitial lung disease22
- osteonecrosis of jaw19
- white blood cell count decreased18
- malignant neoplasm progression16
- osteomyelitis16
- fatigue15
- anaemia12
- aspartate aminotransferase increased12
- oedema peripheral12
- pain12
- pyrexia12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 20 |
| 2006 | 20 |
| 2007 | 12 |
| 2008 | 13 |
| 2009 | 22 |
| 2010 | 40 |
| 2011 | 17 |
| 2012 | 30 |
| 2013 | 22 |
| 2014 | 31 |
| 2015 | 19 |
| 2016 | 28 |
| 2017 | 30 |
| 2018 | 9 |
| 2019 | 25 |
| 2020 | 9 |
| 2021 | 12 |
| 2022 | 9 |
| 2023 | 11 |
| 2024 | 8 |
| 2025 | 13 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fareston (Toremifene Citrate)
2024 spending
$41K
Beneficiaries
n/a
60 claims
Per beneficiary
n/a
$36.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $539,095 |
| 2021 | $274,815 |
| 2022 | $96,934 |
| 2023 | $87,881 |
| 2024 | $41,428 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Breast pain.
Bundred NJ · BMJ Clin Evid 2007 · Systematic Review
- Breast pain.
Goyal A · BMJ Clin Evid 2011 · Systematic Review
- Differences between palpable and nonpalpable tumors in early-stage, hormone receptor-positive breast cancer.
Warren SL, Bhutiani N, Agle SC, et al. · Am J Surg 2018 · Multicenter Study, Randomized Controlled Trial
- High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M, Hayes DF, Ellmén J, et al. · Oncology (Williston Park) 1997 · Clinical Trial, Meta-Analysis
- Toremifene versus tamoxifen for advanced breast cancer.
Mao C, Yang ZY, He BF, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Body mass index influences palpability but not stage of breast cancer at diagnosis.
Chagpar AB, McMasters KM, Saul J, et al. · Am Surg 2007 · Comparative Study, Multicenter Study
Sponsor: Kyowa Kirin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.